极性蛋白Pard3在乳腺癌组织中的表达及与临床病理特征的相关性
《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]
- 期数:
- 2021年22期
- 页码:
- 3959-3962
- 栏目:
- 论著（胸部肿瘤）
- 出版日期:
- 2021-10-12
文章信息/Info
- Title:
- Polar protein Pard3 expression in breast cancer and its correlation with clinicopathological characteristics
- Author(s):
- JIANG Qiuxia; FENG Huimin; LI Yansong; ZHANG Yunhong
- Department of Pathology,Hengshui Second People's Hospital，Hebei Hengshui 053000,China.
- 分类号:
- R737.9
- DOI:
- 10.3969/j.issn.1672-4992.2021.22.015
- 文献标识码:
- A
- 摘要:
- 目的：探讨极性蛋白Pard3在乳腺癌组织中的表达及与临床病理特征的相关性。方法:收集2017年6月至2019年12月我院外科行乳腺癌切除术的93例女性乳腺癌患者的乳腺癌组织、癌旁正常组织和临床资料。采用免疫组化技术检测Pard3在乳腺癌组织和癌旁正常组织中的表达情况，并结合临床资料，分析Pard3在乳腺癌组织中的表达量与患者临床病理特征之间的关系。采用二分类的Logistic回归分析进行Pard3在乳腺癌组织中的表达与患者临床病理特征相关性分析。结果:免疫组化结果显示，在乳腺癌组织中Pard3的表达水平明显下降。乳腺癌组织中阳性率为31.2%（29/93），显著低于癌旁正常组织中的阳性率72.0%（67/93），差异有统计学意义（P=0.000）。临床病理特征相关性分析结果显示Pard3的表达与患者年龄、肿瘤大小、病理类型、淋巴结转移情况之间的关系差异无统计学意义（P＞0.05）；与TNM分期、组织分化程度、ER、PR、HER-2、Ki-67表达之间的关系差异有统计学意义（P＜0.05）。经Logistic回归分析结果显示，Pard3的表达与分化程度、ER表达呈正相关，与TNM分期呈负相关，与PR、HER-2、Ki-67表达无相关性。结论:极性蛋白Pard3在乳腺癌组织中的表达显著低于癌旁正常组织，其在乳腺癌组织中的表达量与组织分化程度、ER表达呈正相关，与TNM分期呈负相关。
- Abstract:
- Objective:To investigate the expression of polar protein Pard3 in breast cancer and its correlation with clinicopathological characteristics.Methods:The breast cancer tissue,normal tissues and clinical data of 93 female breast cancer patients who underwent breast cancer resection in our hospital from June 2017 to December 2019 were collected.Immunohistochemical technique was used to detect the expression of Pard3 in breast cancer tissues and normal tissues adjacent to the cancer,and combined with clinical data,the relationship between Pard3 expression in breast cancer tissues and clinical pathological characteristics of patients was analyzed.The Logistic regression analysis of binary classification was used to analyze the correlation between Pard3 expression in breast cancer and clinicopathological characteristics of patients.Results:Immunohistochemical results showed that the expression level of Pard3 in breast cancer tissues decreased significantly.The positive rate in breast cancer tissues was 31.2% (29/93),which was significantly lower than that in normal tissues adjacent to cancer,72.0% (67/93),the difference was statistically significant (P=0.000).The correlation analysis results of clinicopathological characteristics showed that the relationship between Pard3 expression and the patient's age,tumor size,pathological type,and lymph node metastasis were not statistically significant (P＞0.05).There were statistically significant differences in relationship with TNM stage,tissue differentiation,ER,PR,HER-2,Ki-67 expression (P＜0.05).Logistic regression analysis showed that Pard3 expression was positively correlated with the degree of differentiation and ER expression,but negatively correlated with TNM stage,and had no correlation with PR,HER-2 and Ki-67 expression.Conclusion:The expression of polar protein Pard3 in breast cancer tissue is significantly lower than that in normal tissues adjacent to the cancer.Its expression in breast cancer tissue is positively correlated with tissue differentiation and ER,and negatively correlated with TNM stage.
参考文献/References
［1］ PAMPINA P,GEORGE G,YIALLOUROU AI,et al.Epidemiology of breast cancer in Cyprus:Data on newly diagnosed cases and survival rates［J］.Data in Brief,2018,9(19):353-369.
［2］ BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2018,68(6):394-424.
［3］ HAPAK SM,ROTHLIN CV,GHOSH S.PAR3-PAR6-atypical PKC polarity complex proteins in neuronal polarization［J］.Cellular and Molecular Life Sciences,2018,75(15):2735-2761.
［4］ ZHOU PJ,WANG X,AN N,et al.Loss of Par3 promotes prostatic tumorigenesis by enhancing cell growth and changing cell division modes［J］.Oncogene,2018,38(12):2192-2205.
［5］ 刘炜圳,万文泽,阮拓,等.极性蛋白PARD3对结直肠癌转移的影响［J］.中华实验外科杂志,2017,34(10):1768-1770.
LIU WZ,WAN WZ,RUAN T,et al.Effect of polar protein PARD3 on colorectal cancer metastasis ［J］.Chinese Journal of Experimental Surgery,2017,34(10):1768-1770.
［6］ ZHENG JH,JIAO SJ,NA L,et al.Defective expression of polarity protein Par3 promotes cervical tumorigenesis and metastasis［J］.European Journal of Gynaecological Oncology,2017,38(2):199-206.
［7］ GOMES MD,LETZIAN S,SAYNISCH M,et al.Polarity signaling ensures epidermal homeostasis by coupling cellular mechanics and genomic integrity［J］.Nature Communications,2019,10(1):3362.
［8］ 李涛,杨学军.Par3在肿瘤中的表达及作用［J］.中华实验外科杂志,2017,34(10):1798-1801.
LI T,YANG XJ.Expression and role of Par3 in tumor ［J］.Chinese Journal of Experimental Surgery,2017,34(10):1798-1801.
［9］ GUO CF,ZHAO JD,MA JQ.Expression of polar protein Par3 in cervical squamous cell carcinoma and its clinical significance ［J］.Chin J Med,2019,16(21):93-96，190.
［10］ SONG T,TIAN X,KAI F,et al.Loss of Par3 promotes lung adenocarcinoma metastasis through 14-3-3ζ protein［J］.Oncotarget,2016,7(39):64260-64273.
［11］MESCHER M,JEONG P,KNAPP SK,et al.The epidermal polarity protein Par3 is a non-cell autonomous suppressor of malignant melanoma［J］.The Journal of Experimental Medicine,2017,214(2):339-358.
［12］ ZHOU Q,DAI J,CHEN T,et al.Downregulation of PKC zeta/Pard3/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion［J］.Cellular Signalling,2017,12(38):49-59.
［13］ LI J,XU H,WANG Q,et al.Pard3 suppresses glioma invasion by regulating RhoA through atypical protein kinase C/NF-κB signaling［J］.Cancer Medicine,2019,8(5):2288-2302.
［14］ 于喜法,秦合军.ER、PR、C-erbB-2、p53和Ki-67在乳腺癌组织中的表达及与其临床病理特征相关性［J］.实用癌症杂志,2018,33(01):39-42.
YU XF,QIN HJ.Expression of ER,PR,C-erbB-2,p53 and Ki-67 in breast cancer tissues and their correlation with their clinicopathological features ［J］.Journal of Applied Cancer,2018,33(01):39-42.
［15］ 王光辉,唐亚楠,陈楠,等.新辅助化疗对乳腺癌患者ER、PR、HER-2及Ki67表达的影响［J］.西安交通大学学报(医学版),2018,39(04):542-545,588.
WANG GH,TANG YN,CHEN N,et al.Effects of neoadjuvant chemotherapy on the expression of ER,PR,HER-2 and Ki67 in breast cancer patients ［J］.Journal of Xi'an Jiaotong University (Medical Edition),2018,39(04):542-545,588.
备注/Memo
- 备注/Memo:
- 河北省卫生健康委员会联合基金项目（编号：WJ2018H238）
